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ABSTRACT
Dysfunction of the human trabecular meshwork (HTM) plays a central role in 
the age-associated disease glaucoma, a leading cause of irreversible blindness. The 
etiology remains poorly understood but cellular senescence, increased stiffness of 
the tissue, and the expression of Wnt antagonists such as secreted frizzled related 
protein-1 (SFRP1) have been implicated. However, it is not known if senescence is 
causally linked to either stiffness or SFRP1 expression. In this study, we utilized 
in vitro HTM senescence to determine the effect on cellular stiffening and SFRP1 
expression. Stiffness of cultured cells was measured using atomic force microscopy 
and the morphology of the cytoskeleton was determined using immunofluorescent 
analysis. SFRP1 expression was measured using qPCR and immunofluorescent 
analysis. Senescent cell stiffness increased 1.88±0.14 or 2.57±0.14 fold in the 
presence or absence of serum, respectively. This was accompanied by increased 
vimentin expression, stress fiber formation, and SFRP1 expression. In aggregate, 
these data demonstrate that senescence may be a causal factor in HTM stiffening 
and elevated SFRP1 expression, and contribute towards disease progression. These 
findings provide insight into the etiology of glaucoma and, more broadly, suggest a 
causal link between senescence and altered tissue biomechanics in aging-associated 
diseases.
INTRODUCTION
Glaucoma is a family of irreversible blinding 
diseases that are projected to affect 79.6 million people 
worldwide by the year 2020 [1]. The most common 
form of glaucoma, primary open angle glaucoma, is an 
aging associated disease (AAD) often characterized by 
elevated intraocular pressure induced by increased outflow 
resistance of the aqueous humor [2]. The human trabecular 
meshwork (HTM), a complex three-dimensional structure 
comprised of cells, interwoven collagen beams and 
perforated sheets, is believed to provide the majority of 
outflow resistance in both normal and glaucomatous eyes 
[3-7]. HTM cells, depending on the region of the HTM, 
either form sheets covering extracellular matrix (ECM) 
structures or are scattered throughout the ECM [8-11]. 
What changes in the HTM resulting in increased resistance 
is poorly understood, but our recent study showed the 
HTM is ~20 fold stiffer in glaucoma [12], suggesting a 
prominent role of HTM mechanobiology. This tissue-scale 
stiffening is likely a result of biophysical changes to both 
the ECM and constituent cells, as structural changes to 
both the cytoskeleton [13, 14] and ECM [15-19] have long 
been associated with glaucoma.
Building upon these findings, further research has 
led to a growing body of evidence that these biophysical 
changes are not epiphenomena, but upstream of factors 
important in the progression of the disease. In vitro studies 
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by our lab and others have shown that primary HTM cells 
have alterations in expression of genes associated with 
glaucoma, in biophysical properties, and in responsiveness 
to potential therapeutics when grown on hydrogels of 
varying stiffness [20-25]. Importantly, when cultured 
on hydrogels mimicking the stiffness of glaucomatous 
HTM, HTM cells increased expression of genes known 
to be associated with glaucoma progression [26-34], 
including myocilin [21, 23], secreted protein acidic and 
rich in cysteine (SPARC) [23], and secreted frizzled 
related protein-1 (SFRP1) [21]. These studies suggest 
a mechanism by which altered HTM mechanobiology 
reinforces the biological mediators of the glaucomatous 
phenotype. However, it remains unclear what processes 
induce stiffening.
A prime candidate for this process is cellular 
senescence, the irreversible arrest of cellular proliferation. 
Senescence is thought to contribute to many of the 
physiological changes associated with aging as well 
as AAD [35-40]. Induction of senescence generally 
occurs either due to telomere shortening after repeated 
mitosis (“replicative senescence”) or presentation of 
physiological stress (“stress-induced senescence”), 
although the distinction is blurry at best [35, 38, 41-47]. 
Both telomere shortening and cellular senescence are 
correlated with aging [48-52], and this is hypothesized 
as a prime driver of aging and associated diseases [53, 
54]. Increased cell senescence is observed in the HTM 
of glaucoma patients [55], and glaucoma is likewise one 
among many AADs associated with increased rigidity 
of the tissue.  Other AADs known to be associated with 
increased tissue stiffness include atherosclerosis [56-58], 
age-related macular degeneration [59-62], and cancer 
microenvironments [63-65]. Improved understanding 
of the causes of HTM stiffening in glaucoma will likely 
provide insight into other AADs as well.
Senescence is associated with increased expression 
of vimentin [66, 67] and filamentous actin (F-actin) 
[68-70], both of which are key determinants of cellular 
mechanics [71-74]. Both cytoskeletal elements are 
expressed in HTM cells [75-77], and altered F-actin 
morphology has been associated with HTM dysfunction 
[13, 14, 78-80]. Additionally, we have recently shown that 
exogenous SFRP1 induces pronounced and long-lasting 
stiffening of HTM cells [81]. SFRP1 has been shown to be 
necessary and sufficient for the induction of the senescent 
phenotype [82], suggesting SFRP1 induced stiffening 
may be related to senescence as well. In aggregate, there 
is strong support for a hypothesis of cellular senescence 
contributing to the glaucoma phenotype by increasing 
cellular stiffening associated with cytoskeletal changes. 
However, senescence has yet to be directly linked to HTM 
mechanobiology.
In this study, primary HTM cells were serially 
passaged until senescence and atomic force microscopy 
(AFM) was used to measure the intrinsic mechanical 
properties of senescent cells compared to normally 
proliferating controls. We found that stiffness was 
significantly increased in high passage HTM cells, and this 
was associated with increased staining of vimentin and 
F-actin. Further, SFRP1 expression was also elevated in 
senescent cultures. In aggregate, these results demonstrate 
HTM cellular senescence profoundly alters HTM 
mechanobiology and suggest a causal link between HTM 
cell senescence, altered cell mechanics and glaucoma 
progression.
RESULTS
Confirmation of senescence
For all experiments, we serially passaged primary 
HTM cells until a complete loss of proliferative response 
was observed. Failure of proliferation was defined as 
having equal to or fewer viable cells one week after plating 
of a given passage. In these cultures, the cells took on an 
enlarged, flattened morphology, typical of senescent cells 
[83-88]. To confirm this method resulted in senescence, 
we plated cells of three donors (HTM553, HTM667, 
HTM631) on glass coverslips and assayed for senescence 
associated β-galactosidase (SAβGal) activity, a known 
marker of senescence [52, 89, 90]. In terminally passaged 
HTM cells, prominent blue staining indicates SAβGal 
activity which is minimal at earlier passages (Figure 
1). Under these culture conditions, HTM cells typically 
senesced at passages 12-15, although cells isolated from 
some donors senesced earlier.
Measurement of stiffness with increasing passage
Having established an in vitro model of HTM 
senescence, we turned to the primary objective of our 
study, determining if senescent HTM cells are intrinsically 
stiffer. We serially passaged primary HTM cells from 7 
donors and measured cellular mechanics using AFM 
at each passage. Values of representative donor 517 are 
shown for passage 7 through senescence at passage 12 
(Figure 2A). Minimal variation or serum dependence was 
observed at lower passages; the calculated elastic modulus 
of proliferating cells were similar to previously published 
values for HTM cells [25, 81, 91]. At terminal passage 
cells were substantially stiffer in full media, while the 
last three passages of cells in serum free media exhibited 
substantial stiffening. One way ANOVA and Bonferroni 
comparison to the earliest passage revealed these 
differences were significant to at least the p < 0.05 level, 
demonstrating a passage effect with cells from this donor. 
We performed similar experiments with cells derived from 
6 other donors, observing similar results (Figure 2B-2G). 
Stiffness at or immediately before terminal passage was 
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typically elevated in full media and/or serum free media, 
although the response in serum free media was more 
robust. Despite the apparent trend, there was substantial 
donor variability both in baseline stiffness and effect 
of passage. To control for donor-to-donor variability, 
we normalized the measurements of the senescent cells 
at terminal passage to proliferative cells at the earliest 
passage (Figure 2H). Senescent cell populations were 
1.88±0.14 (n=7 donors; p < 0.05) or 2.57±0.14 (n=7 
donors; p < 0.01) fold stiffer than proliferative controls in 
the presence or absence of serum, respectively.
Staining of actin and vimentin with passage
As both intermediate filaments and the actin 
cytoskeleton have been linked to cell stiffness and 
senescence [66-74], we fixed and stained proliferative 
and senescent cultures for vimentin and F-actin (Figure 
3A-B). In proliferative cultures, vimentin was minimally 
expressed in the cell body but the expression was greatly 
increased in senescent cells. Similarly, proliferative HTM 
cultures exhibited numerous stress fibers as previously 
reported [14, 75, 79, 80], however, after senescence the 
stress fibers became more prominent. To quantify these 
changes, we averaged staining intensity of vimentin and 
F-actin for both senescent and proliferative cultures from 
4 different donors (Figure 3C-3D). Senescent cultures 
exhibited significantly brighter staining intensity of 
vimentin, both in full (1.46±0.19 fold; p < 0.05) and serum 
free (1.57±0.18 fold; p < 0.05) media. Similar results were 
obtained with F-actin staining for full (1.52±0.25 fold; p = 
0.086) and serum free (1.53±0.17 fold; p < 0.05) culture, 
although the results did not rise to significance in full 
media cultures.
Expression of SFRP1 with passage
Finally, as we have previously linked exogenous 
SFRP1 to increased HTM cellular stiffness, we used 
immunofluorescence and qPCR to assay the expression 
of SFRP1 in proliferative and senescent cultures of 3 
different donors. Proliferative HTM cultures stained 
positive for SFRP1 (Figure 4A), but this was greatly 
increased in senescent cells (Figure 4B). SFRP1 staining 
intensity was increased 1.6131±0.15 fold (p<0.05) in 
full media and 1.7211±0.31 fold (p = 0.080) in serum 
free cultures (Figure 4C). Additionally, we used qPCR to 
quantify SFRP1 mRNA expression. In serum free cultures 
of 3 different donors, SFRP1 was upregulated 4.18±1.07 
fold (p < 0.05) with senescence.
DISCUSSION
This study demonstrates senescence plays a 
prominent role in HTM mechanobiology. Utilizing serial 
passage of primary cells as an in vitro means of inducing 
senescence, this study demonstrates profound increases in 
cellular stiffness in senescent HTM cell populations. The 
increase occurred in the presence of serum but appeared 
more robust in serum free culture. This difference was 
an unexpected finding, and the role of serum signaling in 
senescence associated stiffening requires further study. 
The increase is correlated with, and likely related to, 
increases in vimentin, F-actin, and SFRP1 expression. 
Figure 1: HTM cells exhibit hallmarks of senescence at advanced passage. (A) HTM cells under routine culture are relatively 
small and elongated, and have minimal SAβGal activity. (B) After serial passaging, HTM cells assume a senescent phenotype included an 
enlarged, flattened morphology, and pronounced SAβGal activity. Images are of HTM728 (passages 5 and 7) and are representative of cells 
from other donors. Scale bars are 50 μm.
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Figure 2: Intrinsic stiffness of HTM cells is increased in senescent populations. (A) HTM cells from donor 517 underwent 
serial passaging and stiffness (Ecell) was measured each passage for both full and serum free media conditions. At terminal passage, stiffness 
is substantially upregulated. (B-G) HTM cells from 6 other donors (627, 621, 728, 667, 553, and 554) similarly were serially passaged to 
senescence, and similarly exhibited stiffening at terminal passage. Data are mean±SEM. † p < 0.05 with respect to earliest passage. (H) For 
all 7 donors, the average elastic modulus at terminal passage (‘Senesce.’) was normalized to average elastic modulus at the earliest passage 
(‘Prolif.’). For each donor and each condition, 5-7 cells were each indented 5-7 times and averaged. Data are mean±SEM. * p < 0.05; ** 
p < 0.01.
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Figure 3: HTM cells exhibit more pronounced cytoskeleton at senescence. (A) HTM cells under routine culture stain positively 
for both F-actin (red) and vimentin (green). DAPI used as nuclear counterstain (blue). (B) After serial passaging, HTM cells exhibit more 
pronounced stress fibers and brighter vimentin staining. Images are of HTM728 (passages 5 and 7) and are representative of cells from 
other donors. Scale bars are 50 μm. (C) Quantification of the average vimentin staining intensity reveals a significantly increased signal in 
senescent cultures when compared earlier passages (n=4). (D) Similar results are observed with average F-actin staining intensity, however, 
only serum free cultures demonstrate statistical significance (n=4). Data are mean±SEM. * p < 0.05.
Figure 4: Elevated SFRP1 expression is a phenotype of HTM senescence. (A) HTM cells under routine culture (HTM667; 
passage 6) stain positive for SFRP1 (green). DAPI is used as a nuclear counterstain. Scale bar is 50 μm. (B) After serial passaging, senescent 
HTM cells (HTM667; passage 10) exhibit a substantial increase in SFRP1 staining intensity. Images are of HTM667 (passages 6 and 10) 
and are representative of cells from other donors. Scale bars are 50 μm. (C) Quantification of the average SFRP1 staining intensity reveals 
a significantly increased signal in senescent cultures when compared earlier passages for full media cultures (n=3). While elevated, serum 
free cultures are not significant. (D) SFRP1 is elevated at the message level in serum free senescent cultures relative to earlier passages 
(n=3). Data are mean±SEM. * p < 0.05.
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Importantly, these data fill in crucial knowledge gaps in 
our understanding of HTM mechanobiology and build on 
previous work.
Our lab has shown that the HTM in glaucoma 
is ~20 fold stiffer [12], and available data suggests this 
is due to changes in both cytoskeletal dynamics and 
extracellular matrix [13-19]. Further, it is likely that these 
changes are coupled, as we have previously shown that 
HTM cells grown on stiffer matrices will have increased 
intrinsic stiffness [25] and elevated SFRP1 expression 
[21]. Despite the correlation of glaucoma with HTM 
stiffness, there is a paucity of data directly linking 
biological phenotypes of glaucoma with stiffening of the 
cells or matrix. Recently, we have shown that transforming 
growth factor β signaling, implicated in glaucoma, causes 
HTM cells to deposit a physically stiffer matrix with 
elevated SFRP1 secretion [92]. In a separate study, we 
demonstrated SFRP1, also associated with glaucoma, 
induces intrinsic stiffening of HTM cells [81]. Adding 
to these recent studies, we have now identified a third 
potential contributor to the overall stiffness of the HTM in 
glaucoma: cellular senescence.
It is instructive to consider the magnitude of the 
baseline HTM cell stiffness and the stiffening associated 
with senescence. As mentioned in the results, the baseline 
cellular stiffness is consistent with previous data on HTM 
cells [25, 81, 91] and is within the range previously 
reported for various cell types [93]. Further, the 2-3 fold 
change in HTM cellular stiffness with senescence is 
comparable to differences observed between metastatic 
and non-metastatic cancer cells [94-99], suggesting 
this difference could be coupled to dramatic functional 
changes. However, it is important to note that a 2-3 fold 
change is substantially smaller than the ~20 fold stiffening 
observed with glaucoma [12], suggesting senescence is 
but one of the factors contributing to HTM stiffening in 
vivo. The consequence that stiffening of cells has on ECM 
deposition and remodeling, particularly as it senesces, is 
poorly understood and warrants further investigations.
While the mechanisms underlying senescence-
associated stiffening remain incompletely defined, it 
is likely cytoskeletal reorganization plays a key role. 
In numerous other studies, senescent cells or those 
from aged organisms exhibited marked changes to 
their cytoskeleton [66-70]. In this study, we stained for 
vimentin and F-actin, as both are known to be expressed 
in HTM [75-77] and relevant to cell stiffness [71-74]. 
Microtubules, while expressed in the HTM and altered in 
senescence [100-103], have been shown to have minimal 
impact on cellular mechanics [104, 105]. Another likely 
contributor, not explored in this study, is changes to the 
nuclear lamins, which contribute to nuclear stiffness [106, 
107]. There is a well understood connectivity between 
the cytoskeleton and the lamina [108-110] and we feel it 
likely that the cytoskeletal alterations we have described 
are coupled with changes in lamin morphology. Indeed, 
the premature aging disease Hutchinson-Gilford progeria 
syndrome is linked to a splice variant of Lamin A, 
progerin [111, 112]. Progerin accumulation in cells leads 
to severe functional impairments [113-120], is associated 
with in vitro senescence [121], and has been identified 
in normal aging [122, 123]. As our studies utilize the 
nucleus as a consistent landmark for AFM indentation, 
the role of lamins is especially relevant. Future studies 
will investigate the role of lamin isoform expression in 
senescence associated stiffness.
We determined that SFRP1 is upregulated in HTM 
senescence (Figure 4), consistent with a previous report 
in different cell types [82]. SFRP1 is a potent inhibitor of 
Wnt signaling [124, 125], a key pathway that regulates 
numerous processes, including proliferation [126-129]. 
The findings of the current study serve to link findings 
from numerous previous reports by our lab and others. 
First, SFRP1 itself has been implicated in increased 
resistance to aqueous humor outflow in the HTM [32, 33], 
suggesting that senescence associated SFRP1 expression 
could directly hinder HTM function. Second, we have 
recently shown that SFRP1 induces HTM cell stiffening 
[81], providing a mechanism for a subpopulation of 
SFRP1 secreting cells to spread stiffening throughout the 
tissue. Third, HTM cells grown on hydrogels that mimic 
the stiffness of the glaucomatous HTM have increased 
stiffness as well as increased expression of SFRP1 [21, 
25], suggesting that SFRP1 will be upregulated in the 
presence of tissue stiffening. Finally, high expression 
of SFRP1 has been shown to be sufficient to induce 
senescence in otherwise normal cells [82]. In aggregate, 
these data point to a feedback loop, where exposure to 
SFRP1 induces stiffening and senescence, which in turn 
induces further stiffening and SFRP1 expression/secretion 
to the extracellular milieu capable of affecting adjacent 
cells, compromising HTM function, and ultimately leading 
to glaucoma progression.
It is important to note that the above studies were 
performed on cells isolated from a range of donor ages 
(51-72 y.o.). It is possible that some of the observed donor 
variability is due to age, however, limited availability of 
tissue from a wide range of ages hinders the ability to 
properly explore these effects. As such, the above findings 
were not analyzed with respect to donor age due to the 
limited diversity of tissues.
Finally, while this study was performed specifically 
on HTM cells in the context of glaucoma, it potentially 
has broad applicability. Glaucoma exhibits many of the 
hallmarks of AADs, including fibrosis [15, 27, 130-133], 
oxidative stress [134-139], and loss of cellularity [55, 140-
142]. It is quite possible the finding of increased stiffness 
with senescence is an aspect of many AADs. If so, further 
research into the causes and effects of this stiffening may 
identify novel therapeutic targets for treatment of a broad 
number of aging-associated diseases.
This study demonstrates a direct link between 
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cellular senescence, intrinsic cell stiffening, and SFRP1 (a 
potent inhibitor of canonical Wnt signaling) expression in 
the HTM, all phenotypes associated with glaucoma. Taken 
with previous findings that SFRP1 can induce senescence 
and stiffening, these results suggest cellular senescence 
and resulting SFRP1 expression would induce further 
senescence and stiffening in neighboring cells, reinforcing 
and spreading the senescent phenotype and potentially 
leading to ocular hypertension and glaucoma. The 
identification of this feedback loop could have important 
ramifications for the design of effective therapeutics. 
Further, as glaucoma has many of the hallmarks of AADs, 
there is substantial potential that these findings may 
provide insight into other AADs.
MATERIALS AND METHODS
Culture of HTM cells and serial passaging
All experiments were performed in compliance with 
the Declaration of Helsinki. Primary HTM cells were 
isolated from eight donor corneoscleral rims (Saving Sight 
Eye Bank, St. Louis, MO) as described previously [143]. 
Cells derived from each donor are given a unique 3 digit 
identifier. For this study, HTM cells HTM517, HTM553, 
HTM554, HTM621, HTM627, HTM631, HTM667, 
and HTM728 were isolated from donors of age 51, 55, 
55, 62, 62, 63, 66, and 72. HTM cells were cultured in 
DMEM/F12 (Hyclone, Logan, UT) with 10% fetal bovine 
serum (Atlanta Biologicals, Lawrenceville, GA) and 
2 mM penicillin, streptomycin, amphotericin-B (Life 
Technologies, Carlsbad, CA). HTM cells were plated on 
glass coverslips at a 25,000 cells/cm2 and allowed to attach 
overnight. In order to isolate the influence of serum, cells 
were washed the following day and incubated in either 
serum-containing media (full media) or serum free media 
for three days before analysis.
Cells were routinely passaged at approximately 
90% confluence. Cultures were continued at 1x106 cells 
per 75 cm2 tissue culture flask. Cells were determined to 
be senescent when they failed to proliferate and exhibited 
a flattened, enlarged morphology. Failure of proliferation 
was determined by cell count (Cellometer Vision; 
Nexcelom, Lawrence, MA) as having equal to or fewer 
viable cells one week after plating of a given passage. 
A similar methodology has previously been successful 
at inducing a senescent phenotype in porcine trabecular 
meshwork cells [144]. This methodology was confirmed 
by the prominent expression of senescence associated 
β-galactosidase, assayed with a commercial kit (5 donors; 
Cell Signaling Technology, Danvers, MA). Cultures 
typically become predominantly senescent at passages 10 
to 15, although 2 sets of donor cells senesced as early as 
passage 7.
Atomic force microscopy analysis
Cell mechanics were determined as described 
previously using the Asylum MFP-3D-Bio AFM [25, 
91]. Cells were rinsed in Hanks’ Balanced Salt Solution 
(Hyclone, Logan, Utah), equilibrated on the AFM stage 
to minimize thermal drift, and indented in contact mode 
with silicon nitride cantilevers with square pyramidal tips 
(PNP-TR-50, Nano World, Switzerland). Prior to each 
experiment, the spring constant and deflection sensitivity 
of the cantilever were determined using thermal tuning 
and constant compliance methods. The elastic modulus (E) 
of each sample was obtained by fitting indentation force 
versus indentation depth to the Hertz model as shown in 
Eq. 1, where F is the force applied by indenter, α is the tip 
half angle (35o), ν is Poisson’s ratio, and δ is indentation 
depth.
 (1)
The Hertz model assumes that the samples were 
linearly elastic, homogenous, and infinitely thick. 
However, in the limit of small deformations, the Hertz 
model can be used for materials (such as cells) which are 
viscoelastic, heterogeneous, and finite [145]. Additionally, 
we assume the cells are incompressible (ν = 0.5), a good 
approximation for biological materials with high water 
content [146-149]. For each sample, approximately 5-7 
cells were indented 5-7 times at 2 µm/s. All indentations 
were centered above the cell nucleus to minimize 
variability.
Immunocytochemical analysis
Cells were washed in HBSS and fixed for 20 
minutes in 4% formaldehyde and 0.25% Triton-X 100 
(Fisher Scientific, Waltham, MA) in phosphate buffered 
saline (PBS) and blocked with 2% bovine serum albumin 
(Fisher), 0.2% gelatin (cold-fish; Sigma-Aldrich), 0.1% 
Tween-20 (Fisher) in PBS for 1 hr. Following blocking, 
cells were stained overnight using rabbit anti-SFRP1 
(Abcam, Cambridge, UK) or rabbit anti-vimentin (Cell 
Signaling Technology, Danvers, MA) with a secondary of 
DyLight 488 conjugated goat anti-rabbit (Fisher). Nuclei 
and filamentous actin were counterstained with DAPI and 
phalloidin conjugated to Alexafluor 594, respectively. 
Cells were rinsed in PBS, mounted, and imaged on a 
Zeiss Axiovert 200 inverted microscope. All acquisition 
settings were kept constant for documentation of the 
same stain type (e.g. all phalloidin imaging utilized the 
same acquisition parameters). A minimum of 8 random 
fields were acquired for each case (approximately 100 
cells). Cell borders were traced using semi-automated 
thresholding algorithm and mean gray scale intensity was 
averaged across the cell covered area across all images. 
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For accurate quantification of the SFRP1 intensity, rolling 
ball background subtraction was employed. All analysis 
was conducted using custom image analysis scripts in 
MATLAB 2008b (Mathworks, Natick, MA). Thresholding 
and background subtraction parameters were manually 
checked for fidelity and applied uniformly across all 
images of a stain.
Quantitative real-time polymerase chain reaction 
(qPCR)
Cells were cultured in 60 mm dishes under SF 
conditions as described above. After 3 days, the cells 
were lysed and mRNA was isolated using an RNeasy kit 
(Qiagen, Venlo, Netherlands) and the relative expression 
of SFRP1 was quantified from the mRNA by qPCR 
using SensiFAST Hi-ROX One-Step mastermix (Bioline, 
Taunton, MA) and Taqman primers (Hs00610060_m1; 
Life Technologies, Carlsbad, CA) using 60 ng of mRNA 
per reaction. Gene expression was normalized to that of 
the endogenous control, 18S rRNA (Hs99999901_s1; Life 
Technologies). Expression of the senescent cultures was 
determined relative to proliferative controls.
Statistics
All experiments were with HTM cells isolated 
from multiple donors. The number of replicates is noted 
for each experimental set. For comparison AFM results 
within an individual donor cells, significance was assessed 
for full and serum free conditions separately using one-
way ANOVA followed by Bonferroni’s post-hoc test. 
Significant differences (p<0.05) from the earliest passage 
are indicated with †. For all other data, fold change 
of senescent cultures was determined in reference to 
control cells (proliferative cells of earlier passage) and 
significance was assessed using Student’s t-test and 
significance denoted by ** = p<0.01, and * = p<0.05. All 
quantification is displayed as mean ± SEM and the number 
of biological replicates is noted.
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